Upconversion fluorescence enables homogeneous immunoassay in whole blood.
Explore the source record for details and available documents.
Blood Chemical Analysis↗
Biomedical subjects
Tero Soukka
Publications and source records attributed to Tero Soukka.
Upconversion fluorescence resonance energy transfer in a homogeneous immunoassay for estradiol.
We recently described a novel homogeneous assay principle based on upconversion fluorescence resonance energy transfer (UC-FRET), where an upconverting phosphor (UCP) is utilized as a donor. The UC-FRET has now been applied to a competitive homogeneous immunoassay for 17beta-estradiol (E2) in serum, using a small-molecular dye as an acceptor. The assay was constructed by employing an UCP coated with an E2-specific recombinant antibody Fab fragment as a donor and an E2-conjugated small-molecular dye, Oyster-556, as an acceptor. Standard curves for the assay were produced both in buffer and in male serum. Sensitized acceptor emission was measured at 600 nm under continuous laser diode excitation at 980 nm. In buffer, the IC50 value of the assay was 1 nM and in serum 3 nM. The lower limits of detection (mean of zero calibrators, 3 SD) were 0.4 and 0.9 nM, respectively. The measurable concentration range extended up to 3 nM in buffer and 9 nM in serum. Equilibrium in the assay was reached in 30 min. The novel principle of UC-FRET has unique advantages compared to present homogeneous luminescence-based methods and can enable an attractive assay system platform for clinical diagnostics and for high-throughput screening approaches.
Estradiol↗
Improved homogeneous proximity-based screening assay of potential inhibitors of 17beta-hydroxysteroid dehydrogenases.
17beta-Hydroxysteroid dehydrogenases (17beta-HSDs) are substrate- and tissue-specific isoenzymes that regulate activation and inactivation of steroid hormones. Up-regulation and downregulation in expression of 17beta-HSDs are linked to onset of many steroid-dependent diseases, such as colon, prostate, and breast cancer; thus 17beta-HSDs are potential drug screening targets. Currently their enzymatic activities are usually measured using laborious chromatographic separations followed by radioactive detection of substrate and product. We have previously reported the use of a homogeneous luminescence resonance energy transfer-based immunoassay for 17beta-estradiol in screening of potential inhibitors of 17beta-HSD type 1 (17beta-HSD-1). By replacing the previously used cell-based enzyme reactions with recombinant enzyme reactions the sensitivity of the screening assay improved considerably. In addition, the single assay was able to detect the influence of a tested compound not only on 17beta-HSD-1 but also on 17beta-HSD type 2 (17beta-HSD-2), catalyzing the opposite reaction. The screening results of the tested molecules obtained from the optimized immunoassay were very similar when compared with the results of high performance liquid chromatography separation analysis. The Z factors were 0.79 and 0.83 for 17beta-HSD-1 and 17beta-HSD-2 assays, respectively. Thus the immunoassay measuring samples converted with the recombinant enzymes was a very suitable method for primary high throughput screening, and it could be used also in further characterization of potential drugs.
17-Hydroxysteroid Dehydrogenases↗
Homogeneous assay technology based on upconverting phosphors.
Upconversion photoluminescence can eliminate problems associated with autofluorescence and scattered excitation light in homogeneous luminescence-based assays without need for temporal resolution. We have demonstrated a luminescence resonance energy-transfer-based assay utilizing inorganic upconverting (UPC) lanthanide phosphor as a donor and fluorescent protein as an acceptor. UPC phosphors are excited at near-infrared and they have narrow-banded anti-Stokes emission at visible wavelengths enabling measurement of the proximity-dependent sensitized emission with minimal background. The acceptor alone does not generate any direct emission at shorter wavelengths under near-infrared excitation. A competitive model assay for biotin was constructed using streptavidin-conjugated Er3+,Yb3+-doped UPC phosphor as a donor and biotinylated phycobiliprotein as an acceptor. UPC phosphor was excited at near-infrared (980 nm) and sensitized acceptor emission was measured at red wavelength (600 nm) by using a microtitration plate fluorometer equipped with an infrared laser diode and suitable excitation and emission filters. Lower limit of detection was in the subnanomolar concentration range. Compared to time-resolved fluorometry, the developed assay technology enabled simplified instrumentation. Excitation at near-infrared and emission at red wavelengths render the technology also suitable to analysis of strongly colored and fluorescent samples, which are often of concern in clinical immunoassays and in high-throughput screening.
Biosensing Techniques↗
Simultaneous use of time-resolved fluorescence and anti-stokes photoluminescence in a bioaffinity assay.
A bioaffinity assay is described where anti-Stokes photoluminescence of inorganic lanthanide phosphors and time-resolved fluorescence of lanthanide chelates are measured from a single microtitration well without any disturbance from these label technologies to each other. Up-converting phosphor (UPC-phosphor) bioconjugate was produced by grinding the commercial, micrometer-sized UPC-phosphors to colloidal, submicrometer-sized phosphor particles and by attaching these phosphors to biomolecules. Experiments were carried out in standard 96-well microtitration plates to determine detection limits, linearity, and cross-talk of UPC-phosphor and europium chelate. In numbers of molecules the lower limits of detection for UPC-phosphor were roughly 3 x 10(3) particles in solution and 1 x 10(4) particles in solid phase, and for europium label same values were 9 x 10(6) and 9 x 10(7) molecules. Linearity of detection was for UPC-phosphor 5 orders of magnitude in solution and over 4 orders of magnitude in solid phase and for europium label over 5 orders of magnitude in solution and over 4 orders of magnitude in solid phase. The cross-talk between the two labels was practically nonexistent. In this study we show that up-converting anti-Stokes photoluminescent phosphors could be employed in bioaffinity assays as very potential labels with significant advantages either alone or together with long-lifetime lanthanide chelates.
Biological Assay↗
Photochemical characterization of up-converting inorganic lanthanide phosphors as potential labels.
We have characterized commercially available up-converting inorganic lanthanide phosphors for their rare earth composition and photoluminescence properties under infrared laser diode excitation. These up-converting phosphors, in contrast to proprietary materials reported earlier, are readily available to be utilized as particulate reporters in various ligand binding assays after grinding to submicron particle size. The laser power density required at 980 nm to generate anti-Stokes photoluminescence from these particulate reporters is significantly lower than required for two-photon excitation. The narrow photoluminescence emission bands at 520-550 nm and at 650-670 nm are at shorter wavelengths and thus totally discriminated from autofluorescence and scattered excitation light even without temporal resolution. Transparent solution of colloidal bead-milled up-converting phosphor nanoparticles provides intense green emission visible to the human eye under illumination by an infrared laser pointer. In this article, we show that the unique photoluminescence properties of the up-converting phosphors and the inexpensive measurement configuration, which is adequate for their sensitive detection, render the up-conversion an attractive alternative to the ultraviolet-excited time-resolved fluorescence of down-converting lanthanide compounds widely employed in biomedical research and diagnostics.
Immunoassay↗
Enzyme inhibitor screening using a homogeneous proximity-based immunoassay for estradiol.
The authors have previously reported a homogeneous time-resolved fluorescence proximity immunoassay for estradiol. The assay was based on luminescence resonance energy transfer between a long lifetime fluorescent europium(III) chelate-dyed nanoparticle donor and a short lifetime, near-infrared fluorescent acceptor. The energy transfer prolonged the lifetime of the sensitized acceptor emission, and the fluorescence of the acceptor was measured using a time-resolved detection. The developed immunoassay was employed to screen inhibitors for enzyme 17beta-hydroxysteroid dehydrogenase type 1. The enzyme overexpressed in MCF-7 cells catalyzed a reversible conversion of estroneto17beta-estradiol. The inhibition efficiency of the tested molecule was obtained by comparing the final concentration of converted estradiol after 60 min of conversion reaction in a sample and in a conversion control not containing an inhibitor. The Zbeta factor calculated using the E2 concentrations of the homogeneous assay was 0.64, demonstrating a relatively good performance of the assay. The results from the homogeneous assay were comparable with the results obtained using radioactively labeled estrone as a substrate and high-performance liquid chromatography (HPLC) separation of estrone and converted estradiol after the enzyme reaction. Thus, this homogeneous assay can simplify the primary screening of potential new drug molecules by replacing a tedious radiometric HPLC method.
17-Hydroxysteroid Dehydrogenases↗
[Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin].
Explore the source record for details and available documents.
Aged↗
[Emergency care and follow-up of traumatic dental injuries].
Explore the source record for details and available documents.
Emergency Treatment↗
A sensitive adenovirus immunoassay as a model for using nanoparticle label technology in virus diagnostics.
BACKGROUND: Currently, PCR-based hybridization assays are widely applied in adenovirus diagnostics. However, the technology requires tedious sample preparation, and the amplification phase is susceptible to various contaminants leading to inconvenient and time-consuming assay procedure. Methods relying on viral antigen detection, e.g. immunofluorometric assays (IFMAs) and enzyme immunoassays (EIAs), are less complicated to carry out, but they provide limited sensitivity. OBJECTIVE: Our aim was to develop a simple and sensitive adenovirus assay based on direct antigen detection via sandwich-forming immunoreaction. The assay employed highly fluorescent europium(III)-chelate-doped nanoparticle labels and selection of high affinity monoclonal antibodies (anti-hexon) coated on label particles and microtitration wells. RESULTS AND CONCLUSIONS: The extremely high specific activity of the nanoparticle labels enabled the detection limit over 5000 virus particles per millilitre with purified virus particles. The sensitivity was improved by three orders of magnitude (800-fold) compared to concurrent time-resolved IFMA. Furthermore, the nanoparticle assay showed reasonably low coefficients of variation (4.0-20%) and excellent linearity of more than four orders of magnitude (from below 10(5) to 10(9) virus particles per millilitre). Analyzed nasopharyngeal patient specimens revealed a minor disturbance of matrix components, which could be avoided by dilution. The average signal difference between negative and positive samples was nearly four orders of magnitude. The developed assay was sensitive and more convenient approach to adenovirus screening compared to available assays. In addition, the study demonstrates the potential of nanoparticles in sensitive screening of viral analytes.
Adenovirus Infections, Human↗
Immunoassay of total prostate-specific antigen using europium(III) nanoparticle labels and streptavidin-biotin technology.
Nanoparticle labels conjugated with biomolecules are used in a variety of different assay applications. We investigated the possibility of using europium(III)-labeled 68-nm nanoparticles coated with monoclonal antibodies or streptavidin (SA) to detect prostate-specific antigen (PSA) in serum. The selection of a suitable antibody pair and interference caused by the combination of nanoparticle label and structurally complex analyte were of special interest. A set of antibodies recognizing different epitope areas of PSA was mapped to find the optimal antibody pair for the immunometric nanoparticle-based assay. Different assay configurations were tested to obtain a good correlation with a conventional method based on biotinylated detection antibodies and europium(III) chelate-labeled streptavidin. Monoclonal capture antibody 5E4 was covalently coated on a microtitration well surface; biotinylated 5H6 monoclonal antibody (Mab) was used for detection, and europium(III)-labeled streptavidin-coated nanoparticles were utilized for signal generation. Total PSA concentrations were determined from a panel of male serum samples to test the developed assay. The correlation of the nanoparticle-based and reference assays was good; y=0.9844x-0.1252, R2=0.98, n=27; and the lowest limit of detection of the assay (LLD=0.83 ng/l) was 35-fold lower than for the reference method. The assay application presented here, where a structurally complex analyte is detected, combines the exceptionally high affinity of streptavidin-biotin technology and the high specific activity of long lifetime fluorescence nanoparticle labels. The general characteristics of this combination should permit the development of various immunoassay applications featuring high sensitivity, rapidity, and low consumption of reagents.
Antibodies, Monoclonal↗
Highly sensitive immunoassay of free prostate-specific antigen in serum using europium(III) nanoparticle label technology.
BACKGROUND: Recent proceedings in utilization of europium(III) chelate-dyed polystyrene nanoparticles as labels have combined the advantages of an enhanced monovalent binding affinity and a high specific activity of nanoparticle-antibody bioconjugate. Our objective was to evaluate the performance of the nanoparticle label technology with biological samples in an immunoassay of free prostate-specific antigen (PSA-F) using a standard microtitration well platform. METHODS: Long-lifetime luminescent europium(III)-chelate nanoparticles, 107 nm in diameter, were coated with a PSA-F specific monoclonal antibody. The two-step noncompetitive immunoassay was performed in a microtitration well coated with a second monoclonal antibody. The signal of the surface-bound nanoparticle-antibody bioconjugates was measured directly from the bottom of the well using a standard time-resolved plate fluorometer. RESULTS: The detection limit (mean + 2SD) of the nanoparticle-based PSA-F assay was 0.21 ng/l using a 20-microl sample volume. The assay response was linear up to 5 microg/l, and the functional sensitivity was approximately 0.5 ng/l. The within-run imprecision for spiked serum samples at concentrations 0.0005-0.5 microg/l was 6.4-21.8%, and the within-run and between-run imprecisions for serum samples at concentrations 0.2-2.5 microg/l were 3.4-7.2% and 4.4-7.6%, respectively. The concentrations obtained from serum samples correlated well with the reference immunoassay; slope = 1.018 +/- 0.018; intercept = 0.012 +/- 0.021 microg/l; S(y/x) = 0.112 microg/l; r = 0.993; n = 51. CONCLUSIONS: The developed method demonstrated acceptable performance characteristics allowing clinical studies utilizing patient samples with extremely low concentrations of PSA-F. The present assay detected PSA-F in most of samples from prostatectomized men and in few samples from healthy women that were nondetectable according to the reference immunoassay.
Europium↗
CD44v6 in developing, dysplastic and malignant oral epithelia.
The CD44v6 adhesion molecule has been linked to progression of various carcinomas, but its role in relation to oral-cancer development is not clear. The study was designed to determine whether CD44v6 levels were clinically significant in oral dysplasias. Twenty-nine oral dysplasias were immunostained with CD44v6 antibody on follow-up. Developing normal epithelia and adult normal epithelia and oral carcinomas were stained for comparison. Oral dysplasias and carcinomas exhibited heterogenous staining patterns. No statistically significant correlation between CD44v6 expression and outcome was found for dysplasia patients. The results show that in developing and healthy oral mucosa CD44v6 is associated with epithelium-specific differentiation but in dysplasias and carcinomas it mirrors disorderly epithelial maturation. The results also suggest that determination of CD44v6 levels is not helpful in judging the likely clinical behaviour of oral dysplasia.
Adult↗